Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Delayed Quote SEK

Enorama Pharma AB (publ) (ERMA.ST)

3.0900
0.0000
(0.00%)
At close: April 24 at 3:56:14 PM GMT+2
Loading Chart for ERMA.ST
  • Previous Close 3.0900
  • Open 2.9400
  • Bid 2.4600 x --
  • Ask 2.9500 x --
  • Day's Range 3.0900 - 3.0900
  • 52 Week Range 1.7100 - 8.4800
  • Volume 9,858
  • Avg. Volume 249,109
  • Market Cap (intraday) 186.862M
  • Beta (5Y Monthly) 1.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company was incorporated in 2006 and is based in Malmö, Sweden.

www.enorama.se

5

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ERMA.ST

View More

Performance Overview: ERMA.ST

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

ERMA.ST
8.04%
OMX Stockholm 30 Index (^OMX)
2.26%

1-Year Return

ERMA.ST
23.60%
OMX Stockholm 30 Index (^OMX)
3.90%

3-Year Return

ERMA.ST
86.68%
OMX Stockholm 30 Index (^OMX)
18.35%

5-Year Return

ERMA.ST
91.77%
OMX Stockholm 30 Index (^OMX)
60.29%

Compare To: ERMA.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ERMA.ST

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    186.86M

  • Enterprise Value

    184.78M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.85

  • Price/Book (mrq)

    23.95

  • Enterprise Value/Revenue

    11.72

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -277.82%

  • Return on Assets (ttm)

    -118.33%

  • Return on Equity (ttm)

    -320.44%

  • Revenue (ttm)

    15.77M

  • Net Income Avi to Common (ttm)

    -43.81M

  • Diluted EPS (ttm)

    -0.7200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.08M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -34.96M

Research Analysis: ERMA.ST

View More

Company Insights: ERMA.ST

Research Reports: ERMA.ST

View More

People Also Watch